Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

434 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis.
Becherini C, Visani L, Caini S, Bhattacharya IS, Kirby AM, Nader Marta G, Morgan G, Salvestrini V, Coles CE, Cortes J, Curigliano G, de Azambuja E, Harbeck N, Isacke CM, Kaidar-Person O, Marangoni E, Offersen B, Rugo HS, Morandi A, Lambertini M, Poortmans P, Livi L, Meattini I. Becherini C, et al. Among authors: lambertini m. Cancer Treat Rev. 2023 Sep;119:102586. doi: 10.1016/j.ctrv.2023.102586. Epub 2023 Jun 15. Cancer Treat Rev. 2023. PMID: 37336117 Free article. Review.
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials.
Del Mastro L, Ceppi M, Poggio F, Bighin C, Peccatori F, Demeestere I, Levaggi A, Giraudi S, Lambertini M, D'Alonzo A, Canavese G, Pronzato P, Bruzzi P. Del Mastro L, et al. Among authors: lambertini m. Cancer Treat Rev. 2014 Jun;40(5):675-83. doi: 10.1016/j.ctrv.2013.12.001. Epub 2013 Dec 8. Cancer Treat Rev. 2014. PMID: 24360817 Review.
Targeted agents for cancer treatment during pregnancy.
Lambertini M, Peccatori FA, Azim HA Jr. Lambertini M, et al. Cancer Treat Rev. 2015 Apr;41(4):301-9. doi: 10.1016/j.ctrv.2015.03.001. Epub 2015 Mar 13. Cancer Treat Rev. 2015. PMID: 25795021 Review.
Twenty years of anti-HER2 therapy-associated cardiotoxicity.
Pondé NF, Lambertini M, de Azambuja E. Pondé NF, et al. Among authors: lambertini m. ESMO Open. 2016 Jul 21;1(4):e000073. doi: 10.1136/esmoopen-2016-000073. eCollection 2016. ESMO Open. 2016. PMID: 27843627 Free PMC article. Review.
Adjuvant trastuzumab: a 10-year overview of its benefit.
Lambertini M, Pondé NF, Solinas C, de Azambuja E. Lambertini M, et al. Expert Rev Anticancer Ther. 2017 Jan;17(1):61-74. doi: 10.1080/14737140.2017.1264876. Epub 2016 Dec 5. Expert Rev Anticancer Ther. 2017. PMID: 27883296 Review.
Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
Solinas C, Ceppi M, Lambertini M, Scartozzi M, Buisseret L, Garaud S, Fumagalli D, de Azambuja E, Salgado R, Sotiriou C, Willard-Gallo K, Ignatiadis M. Solinas C, et al. Among authors: lambertini m. Cancer Treat Rev. 2017 Jun;57:8-15. doi: 10.1016/j.ctrv.2017.04.005. Epub 2017 May 2. Cancer Treat Rev. 2017. PMID: 28525810 Review.
434 results